Market closed
BridgeBio Pharma/BBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BridgeBio Pharma
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Ticker
BBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
553
Website
BridgeBio Pharma Metrics
BasicAdvanced
$4.9B
Market cap
-
P/E ratio
-$2.58
EPS
1.06
Beta
-
Dividend rate
Price and volume
Market cap
$4.9B
Beta
1.06
52-week high
$44.32
52-week low
$21.62
Average daily volume
2.2M
Financial strength
Current ratio
4.586
Quick ratio
3.337
Long term debt to equity
-159.809
Total debt to equity
-159.809
Interest coverage (TTM)
-5.78%
Management effectiveness
Return on assets (TTM)
-48.44%
Return on equity (TTM)
37.96%
Valuation
Price to revenue (TTM)
20.856
Price to book
-4.47
Price to tangible book (TTM)
-4.37
Price to free cash flow (TTM)
-10.889
Growth
Revenue change (TTM)
3,761.22%
Earnings per share change (TTM)
-31.32%
3-year revenue growth (CAGR)
51.73%
3-year earnings per share growth (CAGR)
-12.06%
What the Analysts think about BridgeBio Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
BridgeBio Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BridgeBio Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BridgeBio Pharma News
AllArticlesVideos
3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
24/7 Wall Street·2 days ago
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
GlobeNewsWire·3 days ago
BridgeBio to stop development of therapy for genetic disorder
Reuters·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $4.9B as of September 20, 2024.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of September 20, 2024.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of September 20, 2024.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.